We describe a case of a 72-year-old patient suffering from metastatic breast cancer. The disease had progressed slowly and was almost asymptomatic for a significant time. Toxicity, following third-line treatment with lapatinib, was not significant, and side effects were well controlled. The case is an excellent example of a chronic neoplastic disease in a patient who could be defined as “long-surviving”.
JemalA., ThomasA., MurrayT., ThunM.: Cancer statistics, 2002.CA Cancer J Clin, 52: 23–47, 2002.
2.
HonigS.F.: Treatment of metastatic disease.In: Diseases of the Breast, HarrisJ.R., LippmanM.E., MorrowM., HellmanS. (Eds), pp 669–734, Lippincott-Raven, Philadelphia, 1996.
3.
CardosoF., DiL.A., LohrischC., BernardC., FerreiraF., PiccartM.J.: Second and subsequent lines of chemotherapy for metastatic breast cancer: what did we learn in the last two decades?Ann Oncol, 13: 197–207, 2002.
4.
O'ShaughnessyJ.: Extending survival with chemotherapy in metastatic breast cancer.Oncologist, 10 suppl 3: 20–29, 2005.
5.
CameronD., CaseyM., OlivaC., NewstatB., ImwalleB., GeyerC.E.: Lapatinib plus capecitabine in women with HER-2-positive advanced breast cancer: final survival analysis of a phase III randomized trial.Oncologist, 15: 924–934, 2010.
6.
SlamonD.J., Leyland-JonesB., ShakS., FuchsH., PatonV., BajamondA., FlemingT., EiermannW., WolterJ., PegramM., BaselgaJ., NortonL.: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.N Engl J Med, 344: 783–792, 2001.
7.
CameronD., CaseyM., PressM., LindquistD., PienkowskiT., RomieuC.G., ChanS., Jagiello-GruszfeldA., KaufmanB., CrownJ., ChanA., CamponeM., ViensP., DavidsonN., GorbounovaV., RaatsJ.I., SkarlosD., NewstatB., RoychowdhuryD., PaolettiP., OlivaC., RubinS., SteinS., GeyerC.E.: A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses.Breast Cancer Res, Treat Dec, 112: 533–543, 2008.
8.
HughesK.L., SargeantH., HawkesA.L.: Acceptability of the Distress Thermometer and Problem List to community-based telephone cancer helpline operators, and to cancer patients and carers.BMC Cancer, 11: 46, 2011.
